Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-50640

ABSTRACT: Comparative gene expression analysis of the human periodontal ligament in deciduous and permanent teeth

OTHER RELATED OMICS DATASETS IN: PRJNA218149

TISSUE(S): Deciduous Periodontal Ligament, Permanent Periodontal Ligament

PROVIDER: E-GEOD-50640 | ExpressionAtlas | 2015-07-27

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-50640-analysis-methods.tsv	Tabular
	E-GEOD-50640-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-50640-configuration.xml	Xml
	E-GEOD-50640-percentile-ranks.tsv	Tabular
	E-GEOD-50640.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 50

Similar Datasets

TR study of ‘A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (BIGBANG study)&quot

Project description:Primary outcome(s): Cancer related genome analysis, gene expression and molecular characterization analysis

| 2647002 | ecrin-mdr-crc

Identification of the molecular basis of anti-cancer effect of Huaier.

Project description:Intervention type:DRUG Name of intervention:Huaier Dose form / Japanese Medical Device Nomenclature:GRANULES Route of administration / Site of application:ORAL Dose per administration:20? g Dosing frequency / Frequency of use:OTHER, SPECIFY 20g? per day Planned duration of intervention:3 months to extending if necessary Intended dose regimen:20 to 60/day by either bulk or split for 3 months to extended term if necessary detailes of teratment arms:hepatocellular carcinoma, breast cancer, colorectal cancer and related gastrointestinal cancers, urologic cancers including prostate cancer, pancreas cancer, and lung cancer, etc. Comparative intervention name:None Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use: Planned duration of intervention: Intended dose regimen: Primary outcome(s): For mRNA libraries, focus on mRNA studies. Data analysis includes sequencing data processing and basic sequencing data quality control, prediction of new transcripts, differential expression analysis of genes. Gene Ontology (GO) and the KEGG pathway database are used for annotation and enrichment analysis of up-regulated genes and down-regulated genes. For small RNA libraries, data analysis includes sequencing data process and sequencing data process QC, small RNA distribution across the genome, rRNA, tRNA, alignment with snRNA and snoRNA, construction of known miRNA expression pattern, prediction New miRNA and Study of their secondary structure Based on the expression pattern of miRNA, we perform not only GO / KEGG annotation and enrichment, but also different expression analysis. Study Design: Comparative test, None, No, open(masking not used), EXPLORATORY

| 98681 | ecrin-mdr-crc

Differential Protein and Gene Expression in Endocrine and Neuroendocrine Tumors (NET)

Project description:Interventions: Group 1: Quantitative Expression Analysis of the proteom and gene Expression of Primary Tumor, normal tissue, and metastases Primary outcome(s): Disease associated Proteins and Genes Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science

| 2431957 | ecrin-mdr-crc

Clinical trial of Human BRAF Gene V600E Mutation Diagnostic kit (Fluorescence PCR Analysis)

Project description:Interventions: Gold Standard:Fluorescence PCR Analysis;Index test:Human BRAF Gene V600E Mutation Diagnostic kit (Fluorescence PCR Analysis) Primary outcome(s): colorectal cancer;cancerous goiter Study Design: Diagnostic test for accuracy

| 2676654 | ecrin-mdr-crc

TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H).

Project description:Primary outcome(s): 1. Evaluation of genome abnormality and gene expression by omics analysis of tumor etc. 2. TCR repertoire analysis and RNA expression analysis etc. of T cells in tumor tissue and peripheral blood. 3. Prediction and identification of tumor neo-antigen and evaluation of immunogenicity etc. 4. Analyze ctDNA(16S rRNA PCR) and feces of patients with advanced solid malignancies over time to profile and monitor cancer-related genomic alterations 5. Assessment of the relationship between the analysis above and clinical pathological features or therapeutic efficacy etc.

| 2648665 | ecrin-mdr-crc

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

Homo sapiens

Project description:Comparative gene expression profile analysis between native human odontoblasts and pulp tissue

| PRJNA101917 | ENA

Genomics-based molecular epidemiology of human clinical and feedlot cattle C. jejuni isolates in Alberta, Canada

Project description:Oligonucleotide DNA microarrays were used as a platform to compare C. jejuni isolates from feedlot cattle and human clinical cases from Alberta. Comparative genomic hybridization (CGH) analysis was performed on 87 isolates (46 bovine, 41 human) obtained within the same geographical regions and time frame. In addition, We also performed gene association analysis to determine if any genes may be differentially distributed between human and cattle sources or between clusters dominated by either human or cattle isolates (“human enriched” vs “cattle enriched”). Keywords: Comparative Genomic Hybridization; Genomic epidemiology; Gene-association study

2008-10-17 | GSE13228 | GEO

GEP_DKFZ_JMML_DBL

Project description:Gene expression analysis from primary human JMML samples using Illumina Human HT-12 v4

| EGAD00010001430 | EGA

Identification of the molecular basis of anti-cancer effect of Huaier.

Project description:Intervention type:DRUG. Intervention1:Huaier, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:20 to 60/day by either bulk or split for 3 months to extended term if necessary. Control intervention1:None. Primary outcome(s): For mRNA libraries, focus on mRNA studies. Data analysis includes sequencing data processing and basic sequencing data quality control, prediction of new transcripts, differential expression analysis of genes. Gene Ontology (GO) and the KEGG pathway database are used for annotation and enrichment analysis of up-regulated genes and down-regulated genes. For small RNA libraries, data analysis includes sequencing data process and sequencing data process QC, small RNA distribution across the genome, rRNA, tRNA, alignment with snRNA and snoRNA, construction of known miRNA expression pattern, prediction New miRNA and Study of their secondary structure Based on the expression pattern of miRNA, we perform not only GO / KEGG annotation and enrichment, but also different expression analysis.. Timepoint:RNA sequencing of 240 blood samples of 80 cases and its analysis, scheduled from June 30, 2022..

| 2612481 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data